Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin

Acta Virologica

Volumn 53, Issue 1, 2009, Pages 15-20

  Stropkovska A ^a   Mucha, V ^a   Fislova T ^a   Gocnik M ^a   Kostolansky F ^a   Vareckova E ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Avian influenza; Cross reactivity; HA2; Hemagglutinin; Human influenza; Influenza A virus; Monoclonal antibody; Plaque reduction

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BB8; MONOCLONAL ANTIBODY CF2; MONOCLONAL ANTIBODY EB12; MONOCLONAL ANTIBODY FC12; MONOCLONAL ANTIBODY FE1; MONOCLONAL ANTIBODY IIF4; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; EPITOPE; HEMAGGLUTININ HA 2 FUSOGENIC PEPTIDE, INFLUENZA VIRUS; HEMAGGLUTININ HA-2 FUSOGENIC PEPTIDE, INFLUENZA VIRUS; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

AMINO TERMINAL SEQUENCE; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ARTICLE; CLINICAL ASSESSMENT; CROSS REACTION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H7N7; VIRUS REPLICATION; AMINO ACID SEQUENCE; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; MOLECULAR GENETICS; VIRUS CULTURE;

AVES; INFLUENZA A VIRUS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; EPITOPES, B-LYMPHOCYTE; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; MOLECULAR SEQUENCE DATA; PLAQUE ASSAY; VIRUS REPLICATION;

EID: 65549111747     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2009_01_15     Document Type: Article

References (29)

1. Arnon R (2006): A novel approach to vaccine design: epitope-based vaccines. BTi 18, 10-13.
2. Ben-Yedida T, Arnon R (2007): Epitope-based vaccine against influenza. Expert. Rev. Vaccines 6, 939-948. doi:10.1586/14760584.6.6.939 PMid:18034655
3. Chen J, Wharton SA, Weissenhorn W, Calder LJ, Hughson FM, Skehel JJ, Wiley DC (1995): A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc. Natl. Acad. Sci. USA 92, 12205-12209. doi:10.1073/pnas.92. 26.12205 doi:10.1073/pnas.92.26.12205
4. Gerhard W (2001): The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260, 171-190.
5. Gocník M, Fislová T, Sládková T, Mucha V, Kostolanský F, Vareèková E (2007): Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol. 88, 951-955. doi:10.1099/vir.0.82563-0 PMid:17325369
6. Gocník M, Fislová T, Mucha V, Sládková T, Russ G, Kostolanský F, Vareèková E (2008): Antibodies induced by HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J. Gen. Virol. 89, 958-967. doi:10.1099/vir.0.83524-0 PMid:18343837
7. Kostolanský F, Styk B, Russ G (1988): Changes in the influenza virus haemagglutinin at acid pH detected by monoclonal antibodies to glycopolypeptides HA1 and HA2. Arch. Virol. 101, 13-24. doi:10.1007/BF01314648 PMid:2458086
8. Kostolanský F, Mucha V, Slováková R, Vareèková E (2002): Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol. 46, 229-236.
9. Lipatov AS, Govorkova EA, Webby RJ, Ozaki H, Peiris M, Guan Y, Poon L, Webster RG (2004): Influenza: emergence and control. J. Virol. 78, 8951-8959. doi:10.1128/JVI.78.17.8951-8959.2004 PMid:15308692 PMCid: 506949
10. Luke CJ, Subbarao K (2006): Vaccines for pandemic influenza. Emerg. Infect. Dis. 12, 66-72.
11. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, Otvos L, Gerhard W (2003): Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21, 2616-2626. doi:10.1016/S0264- 410X(03)00040-9 PMid:12744898
12. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999): A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1119-1120. doi:10.1038/13436 PMid:10502805
13. Palese P, García-Sastre A (2002): Influenza vaccines: present and future. J. Clin. Invest. 110, 9-13.
14. Palese P (2006): Making better influenza virus vaccines? Emerg. Infect. Dis. 12, 61-65.
15. Russ G, Vareèková E, Styk B (1974): Steric effects in the reaction of influenza virus neuraminidase with antibodies. Acta Virol. 18, 299-306.
16. Russ G, Poláková K, Kostolanský F, Styk B, Vančíková M (1987): Monoclonal antibodies to glycopeptides HA1 and HA2 of influenza virus hemagglutinin. Acta Virol. 31, 374-386.
17. Skehel JJ, Wiley DC (2000): Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569. doi:10.1146/annurev. biochem.69.1.531 PMid:10966468
18. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM (2004): Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect. Dis. 4, 499-509. doi:10.1016/S1473-3099(04)01105-3 PMid:15288823
19. Styk B, Russ G, Poláková K (1979): Antigenic glycopolypeptides HA1 and HA2 of influenza virus hemagglutinin. III. Reactivity with human convalescent sera. Acta Virol. 23, 1-8.
20. Tamura S, Tanimoto T, Kurata T (2005): Mechanism of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58, 195-207.
21. Tkáčová M, Varečková E, Baker IC, Love JM, Ziegler T (1997): Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J. Clin. Microbiol. 35, 1196-1198.
22. Vaccaro L, Cross KJ, Kleinjung J, Straus SK, Thomas DJ, Wharton SA, Skehel JJ, Fraternali F (2005): Plasticity of influenza haemagglutinin fusion peptides and their interaction with lipid bilayers. Biophys. J. 88, 25-36. doi:10.1529/biophysj.104.044537 PMid:15475582 PMCid:1305003
23. Varečková E, Mucha V, Čiampor F, Betáková T, Russ G (1993): Monoclonal antibodies demonstrate accessible HA2 epitopes in minor subpopulation of native influenza virus haemagglutinin molecules. Arch Virol. 130, 45-56. doi:10.1007/BF01318995 PMid:7684894
24. Varečková E, Betáková T, Mucha V, Soláriková L, Kostolanský F, Waris M, Russ G (1995): Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J. Immunol. Methods 180, 107-116. doi:10.1016/0022-1759(94)00307-I PMid:7897242
25. Varečková E, Klimov A, Cox N (2002): Evaluation of the subtype specificity of monoclonal antibodies raised against H1 and H3 subtypes of human influenza A virus hemagglutinins. J. Clin. Microbiol. 40, 2220-2223. doi:10.1128/JCM.40.6.2220-2223.2002 PMid:12037091 PMCid:130739
26. Varečková E, Mucha V, Wharton SA, Kostolanský F (2003a): Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch. Virol. 148, 469-486. doi:10.1007/s00705-002-0932-1 PMid:12607099
27. Varečková E, Wharton SA, Mucha V, Gocník M, Kostolanský F (2003b): A monoclonal antibody specific to the HA2 glycoprotein of influenza A hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol. 47, 229-236.
28. Varečková E, Mucha V, Kostolanský F, Gubareva LV, Klimov A (2008): HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes. Virus Res. 132, 181-186. doi:10.1016/j.virusres.2007.10.004 PMid:18037184 (Pubitemid 351232077)
29. Yewdell JW, Taylor A, Yellen A, Gerhard W, Bächi T (1993): Mutations in or near the fusion peptide of the influenza virus hemagglutinin affect an antigenic site in the globular region. J. Virol. 67, 933-942. (Pubitemid 23032072)